Clinical Trials
105 trialsSapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
ENVISION
UroGen Pharma Ltd.
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Janssen Research & Development, LLC
IMAGINE
Alliance for Clinical Trials in Oncology
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
LEAP-011
Merck Sharp & Dohme LLC
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
Brigham and Women's Hospital
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Optimus
Incyte Corporation
PRESERVE3
G1 Therapeutics, Inc.
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Incyte Corporation
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
National Cancer Institute (NCI)
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Incyte Corporation
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
MacroGenics
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
National Institutes of Health Clinical Center (CC)
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Aprea Therapeutics
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
AUREA
Spanish Oncology Genito-Urinary Group
PEGASUS
European Association of Urology Research Foundation
FORT-2
Bayer
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Hoosier Cancer Research Network
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
IMvigor130
Hoffmann-La Roche
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Daiichi Sankyo
ABLE
University of Michigan Rogel Cancer Center
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Hoosier Cancer Research Network
PemCab
University of Utah
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
University of Washington
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
University of Florida
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
AstraZeneca
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
EV-201
Astellas Pharma Inc
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Eli Lilly and Company
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Pfizer
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Hoosier Cancer Research Network
ATLAS
UroGen Pharma Ltd.
Neoadjuvant Atezolizumab in Localized Bladder Cancer
University of California, San Francisco
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
JAVELIN Bladder 100
Pfizer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
pharmaand GmbH
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC